Radioprotective effects of flurbiprofen and its nitroderivative
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
9708705
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Anti-Inflammatory Agents, Non-Steroidal pharmacology MeSH
- Bone Marrow Cells drug effects MeSH
- Time Factors MeSH
- Flurbiprofen analogs & derivatives pharmacology MeSH
- Granulocytes cytology drug effects MeSH
- Mice, Inbred C57BL MeSH
- Mice, Inbred CBA MeSH
- Mice MeSH
- Leukocyte Count drug effects MeSH
- Lymphocyte Count drug effects MeSH
- Radiation-Protective Agents pharmacology MeSH
- Spleen cytology drug effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Inflammatory Agents, Non-Steroidal MeSH
- Flurbiprofen MeSH
- nitroflurbiprofen MeSH Browser
- Radiation-Protective Agents MeSH
Radioprotective effects of two non-steroidal anti-inflammatory drugs, flurbiprofen (FBP) and its novel nitroderivative flurbiprofen 4-nitroxybutylester (NO-FBP), which exhibits decreased gastrointestinal toxicity, were compared in mice. The drugs were administered in equimolar single doses, 2 hours before whole-body gamma-irradiation of the animals. After a sublethal radiation dose of 6.5 Gy, significantly increased numbers of endogenous haemopoietic spleen colonies and enhanced granulopoiesis were found in mice given either FBP or NO-FBP, when compared to vehicle-treated controls. There were no differences in the effectiveness of either drug to enhance postirradiation haemopoietic recovery. Survival of FBP- or NO-FBP-treated mice subjected to a lethal dose of 9.5 Gy was slightly but insignificantly enhanced, both drugs showing the same effect. These results clearly indicate the ability of both drugs to enhance haemopoietic recovery after sublethal radiation exposure and the absence of unfavourable effects under higher radiation doses. Because of its lower potential for gastrointestinal damage, NO-FBP seems to be a promising drug, which can find a use in the protection of postirradiation myelosuppression.
Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: a review